Clinical trials: Difference, Individual
Hepatic Impairment, Healthy, Hepatic Insufficiency
A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease
The purpose of this study to understand how the study medicine atirmociclib behaves in the body and how safe it is for people with different levels of liver health.
- Conditions
- Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults
- Trial name
- NCT07677358
- Testing
- Atirmociclib
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers Type 2 Diabetes
A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times
The goal of this trial is to find out whether taking semaglutide tablets at different times before and after eating has a similar effect compared to the recommended dosing time.
- Trial name
- NCT04513704
- Testing
- Oral Semaglutide
- Where
- United Kingdom
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Borderline Personality Disorder
A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
This study is open to adults with borderline personality disorder. The purpose of this study is to find out whether a medicine called BI 1358894 helps to reduce symptoms in people with borderline personality disorder.
- Trial name
- NCT04566601
- Testing
- BI 1358894
- Where
- 67 sites in United States, Argentina and 13 more
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim
Coronavirus
Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
Popular title: Clinical study of Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells). Purpose of the study: Main objectives: To evaluate the immunogenicity and safety of Omicron BA.4/5-Delta…
- Trial name
- NCT05850507
- Testing
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant novel coronavirus protein vaccine (CHO cells)
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Healthy Participants
Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #2
The purpose of this study is to verify the intra-individual difference of the SDLP values in driving simulator.
- Trial name
- NCT03413592
- Testing
- Road-tracking test, Car-following test, Harsh-braking test
- Where
- Japan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Healthy
A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart
The main objective of this trial is to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters
- Trial name
- NCT07760246
- Testing
- Verducatib, Moxifloxacin
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06704724
- Testing
- PF-07985045, Gemcitabine, Nab-paclitaxel
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Pfizer
Heart Failure
A Study of Ponsegromab in People With Heart Failure
The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but does not contain the active medicine) to find…
- Trial name
- GARDEN TIMI 74 (NCT05492500)
- Testing
- Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose
- Where
- 122 sites in United States, Australia and 9 more
- Volunteers
- 455 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
With an amendment of the protocol, this study is only open to adults with head and neck cancer. Previously also adults with liver cancer joined.
- Trial name
- NCT05249426
- Testing
- BI 765063, Ezabenlimab, BI 836880
- Where
- 25 sites in United States, France and 9 more
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Geographic Atrophy
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to adults with geographic atrophy, an advanced form of age-related macular degeneration. People can join the study if they are at least 50 years old.
- Trial name
- NCT06006585
- Testing
- BI 771716
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
The main objective of this trial is to investigate the relative bioavailability of batch 1 of the intended commercial tablet formulation (iCF1) of BI 425809 vs batch 2 of the intended commercial tablet formulation (iCF2) of BI…
- Trial name
- NCT03817476
- Testing
- iCF1(T1) 25 milligram BI 425809, iCF2(T2) 25 milligram BI 425809, TF2(R) 25 milligram BI 425809
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overweight, Obesity
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg.
- Trial name
- NCT06564441
- Testing
- Survodutide, Bupropion, Caffeine
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
This study compares the effect and safety of 2 dose schedules for semaglutide (study medicine) in people with type 2 diabetes previously treated with a diabetes medicine similar to semaglutide.
- Trial name
- SUSTAIN SWITCH (NCT04287179)
- Testing
- Semaglutide
- Where
- 25 sites in United States, Austria and 2 more
- Sponsor
- Novo Nordisk A/S
Healthy, Obesity
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way. Participants visit the study site regularly.
- Trial name
- NCT07413913
- Testing
- Survodutide formulation A, Survodutide formulation B2
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Colorectal Carcinoma, Gastric Carcinoma
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread.
- Conditions
- Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06882746
- Testing
- BI 765049
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists.
- Trial name
- NCT05471856
- Testing
- BI 1703880, Ezabenlimab
- Where
- 21 sites in United States, Japan and 4 more
- Volunteers
- 66 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
This study is open to adults with small cell lung cancer and other neuroendocrine tumours that are positive for the tumour marker Delta-like 3 (DLL3).
- Trial name
- NCT05879978
- Testing
- Obrixtamig, Ezabenlimab
- Where
- 8 sites in Belgium, France and 2 more
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Obesity, Type 2 Diabetes
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight.
- Trial name
- NCT07564414
- Testing
- Cagrisema, Semaglutide
- Where
- 303 sites in United States, Argentina and 17 more
- Volunteers
- 2,500 people
- Sponsor
- Novo Nordisk A/S
Healthy
A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood
This trial aims to test how two different formulations of BI 690517 are taken up by the body and how probenecid influences the amount of BI 690517 in the blood.
- Trial name
- NCT06647810
- Testing
- BI 690517 formulation 1, BI 690517 formulation 2, Probenecid
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3821001 administrations of multiple rising doses.
- Trial name
- NCT07908004
- Testing
- BI 3821001
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim